Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care

View ORCID ProfileShamil Haroon, View ORCID ProfileAnuradhaa Subramanian, View ORCID ProfileJennifer Cooper, Astha Anand, View ORCID ProfileKrishna Gokhale, Nathan Byne, Samir Dhalla, Dionisio Acosta-Mena, Thomas Taverner, Kelvin Okoth, Jingya Wang, View ORCID ProfileJoht Singh Chandan, View ORCID ProfileChristopher Sainsbury, View ORCID ProfileDawit Tefra Zemedikun, View ORCID ProfileG Neil Thomas, View ORCID ProfileDhruv Parekh, View ORCID ProfileTom Marshall, View ORCID ProfileElizabeth Sapey, View ORCID ProfileNicola J Adderley, View ORCID ProfileKrishnarajah Nirantharakumar
doi: https://doi.org/10.1101/2020.09.17.20196469
Shamil Haroon
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shamil Haroon
  • For correspondence: s.haroon@bham.ac.uk
Anuradhaa Subramanian
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anuradhaa Subramanian
  • For correspondence: a.subramanian@bham.ac.uk
Jennifer Cooper
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer Cooper
  • For correspondence: j.cooper.5@bham.ac.uk
Astha Anand
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: a.anand.1@bham.ac.uk
Krishna Gokhale
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Krishna Gokhale
  • For correspondence: k.m.gokhale@bham.ac.uk
Nathan Byne
2 Cegedim Health Data, Cegedim Rx, London, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samir Dhalla
2 Cegedim Health Data, Cegedim Rx, London, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: samir.dhalla@cegedimrx.co.uk
Dionisio Acosta-Mena
2 Cegedim Health Data, Cegedim Rx, London, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Taverner
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t.taverner@bham.ac.uk
Kelvin Okoth
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: koo657@student.bham.ac.uk
Jingya Wang
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.wang.6@bham.ac.uk
Joht Singh Chandan
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joht Singh Chandan
  • For correspondence: joht.chandan@nhs.net
Christopher Sainsbury
3 University of Birmingham and Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and Clyde, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher Sainsbury
  • For correspondence: c.sainsbury.1@bham.ac.uk
Dawit Tefra Zemedikun
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dawit Tefra Zemedikun
  • For correspondence: d.t.zemedikun@bham.ac.uk
G Neil Thomas
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G Neil Thomas
  • For correspondence: g.n.thomas@bham.ac.uk
Dhruv Parekh
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dhruv Parekh
  • For correspondence: d.parekh@bham.ac.uk
Tom Marshall
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tom Marshall
  • For correspondence: t.p.marshall@bham.ac.uk
Elizabeth Sapey
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth Sapey
  • For correspondence: e.sapey@bham.ac.uk
Nicola J Adderley
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicola J Adderley
  • For correspondence: n.j.adderley@bham.ac.uk
Krishnarajah Nirantharakumar
1 University of Birmingham;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Krishnarajah Nirantharakumar
  • For correspondence: k.nirantharan@bham.ac.uk
  • Abstract
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction A significant proportion of patients with Coronavirus Disease-19 (COVID-19) have hypertension and are treated with renin-angiotensin system (RAS) inhibitors, namely angiotensin-converting enzyme I inhibitors (ACE inhibitors) or angiotensin II type-1 receptor blockers (ARBs). These medications have been postulated to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The objective of this study was to assess a possible association between prescription of RAS inhibitors and the incidence of COVID-19 and all-cause mortality. Methods We conducted a propensity-score matched cohort study to assess the incidence of COVID-19 among patients with hypertension who were prescribed ACE inhibitors or ARBs compared to patients treated with calcium channel blockers (CCBs) in a large UK-based primary care database (The Health Improvement Network). We estimated crude incidence rates for confirmed/suspected COVID-19 among those prescribed ACE inhibitors, ARBs and CCBs. We used a Cox proportional hazards model to produce adjusted hazard ratios for COVID-19 comparing patients prescribed ACE inhibitors or ARBs to those prescribed CCBs. We further assessed all-cause mortality as a secondary outcome and a composite of accidents, trauma or fractures as a negative control outcome to assess for residual confounding. Results In the propensity score matched analysis, 83 of 18,895 users (0.44%) of ACE inhibitors developed COVID-19 over 8,923 person-years, an incidence rate of 9.3 per 1000 person-years. 85 of 18,895 (0.45%) users of CCBs developed COVID-19 over 8,932 person-years, an incidence rate of 9.5 per 1000 person-years. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ACE inhibitors compared to CCBs was 0.92 (95% CI 0.68 to 1.26). 79 out of 10,623 users (0.74%) of ARBs developed COVID-19 over 5010 person-years, an incidence rate of 15.8 per 1000 person-years, compared to 11.6 per 1000 person-years among users of CCBs. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ARBs compared to CCBs was 1.38 (95% CI 0.98 to 1.95). There were no significant associations between use of ACE inhibitors or ARBs and all-cause mortality, compared to use of CCBs. We found no evidence of significant residual confounding with the negative control analysis. Conclusion Current use of ACE inhibitors was not associated with the risk of suspected or confirmed COVID-19 whereas use of ARBs was associated with a statistically non-significant 38% relative increase in risk compared to use of CCBs. However, no significant associations were observed between prescription of either ACE inhibitors or ARBs and all-cause mortality during the peak of the pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

http://www.encepp.eu/encepp/viewResource.htm?id=35329

Funding Statement

This study was not externally funded. ES reports receiving funding from HDR-UK (PIONEER Hub), Wellcome, MRC, British Lung Foundation and NIHR. DP reports receiving funding from NIHR and MRC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The THIN data collection scheme and research carried out using THIN data were approved by the NHS South-East Multicentre Research Ethic Committee in 2003. Under the terms of the approval, studies must undergo independent scientific review. Approval for this study was obtained from the THIN Scientific Review Committee in June 2020 (SRC protocol reference 20-003-R2).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The study protocol can be accessed at the European Union electronic Register of Post-Authorisation Studies (EU PAS) register.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 18, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care
Shamil Haroon, Anuradhaa Subramanian, Jennifer Cooper, Astha Anand, Krishna Gokhale, Nathan Byne, Samir Dhalla, Dionisio Acosta-Mena, Thomas Taverner, Kelvin Okoth, Jingya Wang, Joht Singh Chandan, Christopher Sainsbury, Dawit Tefra Zemedikun, G Neil Thomas, Dhruv Parekh, Tom Marshall, Elizabeth Sapey, Nicola J Adderley, Krishnarajah Nirantharakumar
medRxiv 2020.09.17.20196469; doi: https://doi.org/10.1101/2020.09.17.20196469
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care
Shamil Haroon, Anuradhaa Subramanian, Jennifer Cooper, Astha Anand, Krishna Gokhale, Nathan Byne, Samir Dhalla, Dionisio Acosta-Mena, Thomas Taverner, Kelvin Okoth, Jingya Wang, Joht Singh Chandan, Christopher Sainsbury, Dawit Tefra Zemedikun, G Neil Thomas, Dhruv Parekh, Tom Marshall, Elizabeth Sapey, Nicola J Adderley, Krishnarajah Nirantharakumar
medRxiv 2020.09.17.20196469; doi: https://doi.org/10.1101/2020.09.17.20196469

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4875)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5362)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1824)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)